Form 4: Avidity CLO Sells Shares for Tax Obligations

Avidity Biosciences' Chief Legal Officer, John B. Moriarty, reported a future sale of 2,245 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• John B. Moriarty, Chief Legal Officer of Avidity Biosciences, Inc. (RNA), reported a sale of common stock.
• The transaction involves 2,245 shares of common stock.
• The shares are to be sold at a weighted-average price of $36.21 per share.
• The sale is scheduled to occur on August 4, 2025.
• Following this transaction, Moriarty will beneficially own 47,755 shares of common stock.
• The sale is a 'sell-to-cover' transaction, mandated by the company's equity incentive plans to satisfy tax withholding obligations from Restricted Stock Unit (RSU) vesting.
• This is not a discretionary trade by the reporting person and is executed under a Rule 10b5-1 plan.

Sentiment

Score: 7

Explanation: The transaction is a routine 'sell-to-cover' sale for tax withholding purposes related to RSU vesting, executed under a Rule 10b5-1 plan. This indicates a pre-planned, non-discretionary event rather than a reflection of the insider's sentiment about the company's future prospects. Such transactions are common and generally viewed as neutral to slightly positive as they are part of standard executive compensation and tax management.

Positives

• The sale is non-discretionary, executed to cover tax withholding obligations from RSU vesting, indicating a pre-planned transaction rather than a change in sentiment.
• The transaction was conducted under a Rule 10b5-1 plan, demonstrating adherence to pre-arranged trading guidelines and enhancing transparency.

Negatives

• The sale of shares by an insider, even for tax purposes, could be misinterpreted as a lack of confidence if the context of the 'sell-to-cover' transaction is not fully understood by all investors.

Risks

• Fluctuations in the company's stock price could impact the value of the remaining shares beneficially owned by the reporting person.

Future Outlook

The filing indicates a future transaction date of August 4, 2025, for the sale of shares, following the vesting of Restricted Stock Units (RSUs) on August 1, 2025. This is a pre-planned event under a Rule 10b5-1 plan, reflecting a routine aspect of executive compensation management.

Management Comments

• The sale was mandated by the Issuer's equity incentive plans to cover tax withholding obligations related to RSU vesting.
• The transaction does not represent a discretionary trade by the reporting person.
• The reporting person executed an instruction letter for the automatic 'sell-to-cover' transaction, intended to satisfy Rule 10b5-1 affirmative defense conditions.

Industry Context

This type of 'sell-to-cover' transaction is a common practice in many industries, particularly in biotechnology and other sectors where executive compensation frequently includes equity awards like Restricted Stock Units (RSUs). It allows executives to meet tax obligations arising from the vesting of these awards without needing to use personal funds.

Comparison to Industry Standards

• The 'sell-to-cover' mechanism for tax withholding is a widely adopted standard practice for equity compensation plans across publicly traded companies, including those in the biotechnology sector.
• Companies like Moderna (MRNA) and BioNTech (BNTX) also utilize similar mechanisms for their executives' equity awards, demonstrating that this transaction aligns with typical corporate governance and compensation practices.

Corporate Governance

Related Party Transactions

• The sale of shares by Chief Legal Officer John B. Moriarty to cover tax withholding obligations related to RSU vesting, as mandated by the company's equity incentive plans.

Stakeholder Impact

• Shareholders: Provides transparency regarding insider stock transactions, confirming a pre-planned, non-discretionary sale for tax purposes, which typically does not signal a change in management's confidence.
• Employees (specifically executives with equity): Confirms the company's established policy for managing tax obligations arising from equity compensation, providing clarity on how RSU vesting is handled.

Next Steps

• The completion of the pre-planned 'sell-to-cover' transaction on August 4, 2025, following RSU vesting on August 1, 2025.

Key Dates

Keywords

Avidity Biosciences, RNA, Form 4, insider trading, stock sale, RSU, Rule 10b5-1, Chief Legal Officer, John B. Moriarty, equity compensation, tax withholding